人 FAM83A 抗体对
01AB02182
Family with sequence similarity 83 member A (FAM83A) is a cytoplasmic and nuclear protein characterized by a conserved DUF1669 domain. It functions as a potent regulator of the EGFR/MAPK and PI3K/AKT signaling pathways and is involved in mitochondrial maintenance. FAM83A directly interacts with beta-catenin and is phosphorylated by SRC-family kinases, which stabilizes beta-catenin and promotes its nuclear translocation to enhance Wnt target gene transcription. Pathologically, FAM83A acts as a transforming oncogene and is frequently overexpressed in several malignancies, most notably breast and pancreatic cancers. Its overexpression drives tumor proliferation, invasion, and anchorage-independent growth, while also conferring resistance to EGFR and PI3K inhibitors. Consequently, FAM83A is recognized as a significant therapeutic target for overcoming drug resistance in cancer treatment.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- FAM83A
- 基因别名
- TSGP
- 蛋白别名
- family with sequence similarity 83 member A; FAM83A
- UniProt
- Q86UY5
- 物种
- Human
产品详情
- 靶点名称
- FAM83A
- 蛋白名称
- family with sequence similarity 83 member A
- 蛋白别名
- Protein FAM83A; Tumor antigen BJ-TSA-9; Tumor-specific gene expressed in prostate protein
- 靶点基因名
- FAM83A
- 基因别名
- TSGP
- UniProt
- Q86UY5
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Family with sequence similarity 83 member A (FAM83A) is a cytoplasmic and nuclear protein characterized by a conserved DUF1669 domain. It functions as a potent regulator of the EGFR/MAPK and PI3K/AKT signaling pathways and is involved in mitochondrial maintenance. FAM83A directly interacts with beta-catenin and is phosphorylated by SRC-family kinases, which stabilizes beta-catenin and promotes its nuclear translocation to enhance Wnt target gene transcription. Pathologically, FAM83A acts as a transforming oncogene and is frequently overexpressed in several malignancies, most notably breast and pancreatic cancers. Its overexpression drives tumor proliferation, invasion, and anchorage-independent growth, while also conferring resistance to EGFR and PI3K inhibitors. Consequently, FAM83A is recognized as a significant therapeutic target for overcoming drug resistance in cancer treatment.